Synthetic immunology: T-cell engineering and adoptive immunotherapy

Wen Si; Cheng Li; Ping Wei

doi:10.1016/j.synbio.2018.08.001

Synthetic immunology: T-cell engineering and adoptive immunotherapy

Synth Syst Biotechnol. 2018 Sep 1;3(3):179-185. doi: 10.1016/j.synbio.2018.08.001. eCollection 2018 Sep.

Authors

Wen Si^{1

2}, Cheng Li², Ping Wei^{1

2}

Affiliations

¹ Center for Quantitative Biology and Peking-Tsinghua Joint Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.
² The MOE Key Laboratory of Cell Proliferation and Differentiation, School of Life Sciences, Peking University, Beijing 100871, China.

Abstract

During the past decades, the rapidly-evolving cancer is hard to be thoroughly eliminated even though the radiotherapy and chemotherapy do exhibit efficacy in some degree. However, a breakthrough appeared when the adoptive cancer therapy [1] was developed, especially T cells armed with chimeric antigen receptors (CARs) showed great potential in tumor clinical trials recently. CAR-T cells successfully elevated the efficiency and specificity of cytotoxicity. In this review, we will talk about the design of CAR and CAR-included combinatory therapeutic applications in the principles of systems and synthetic immunology.

Keywords: Cell therapy; Chimeric antigen receptor (CAR); Immunotherapy; Systems and synthetic biology; Systems and synthetic immunology; T cell signaling; Tumor immunology.

Publication types

Review